Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Temozolomide and Radiotherapy in Pediatric High-Grade Glioma
NCT04267146Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Jul 2019
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in high-grade glioma (HGG), sponsored by Gustave Roussy. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT04267146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04267146.